Literature DB >> 18098288

Cancer incidence among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia.

Alison Reid1, Jane Heyworth, Nicholas H de Klerk, Bill Musk.   

Abstract

The impact of crocidolite exposure on the health of former Wittenoom miners and millers (largely male) has been well documented. Less is known about the health outcomes of the 2,968 women and girls who lived (N = 2,552) and worked (N = 416) in the blue asbestos milling and mining town of Wittenoom between 1943 and 1992. Quantitative exposure measurements were derived from dust studies undertaken over the lifetime of the mine and mill and the township. Incident cancers were obtained from the Western Australian (WA) Cancer Registry and the National Cancer Clearing House. Standardized incidence ratios (SIRS) compared Wittenoom females with the WA female population. Exposure-response relationships were examined using a matched case-control study design. There were (47) mesothelioma and (55) lung cancer cases among the 437 cancers in the Wittenoom females over the period 1960-2005. When compared to the WA female population, Wittenoom women and girls had higher rates of mesothelioma and possibly lung cancer. Mesothelioma incidence rates are increasing with the incidence rate of 193 per 100,000 in the period 2000-2005 being more than double that for the period 1995-1999 at 84 per 100,000. A significant exposure-response relationship was present for mesothelioma, but not for lung cancer. Forty years after the asbestos mine and mill at Wittenoom were closed, there is a high toll from cancer among the former female residents of the town and company workers. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18098288     DOI: 10.1002/ijc.23331

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma.

Authors:  B W Case; J L Abraham; G Meeker; F D Pooley; K E Pinkerton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

2.  Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up.

Authors:  G Berry; A Reid; P Aboagye-Sarfo; N H de Klerk; N J Olsen; E Merler; P Franklin; A W Musk
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

3.  Incidence of Cancer and Asbestos-Related Diseases among Residents Living near Abandoned Asbestos Mines in South Korea: A Retrospective Cohort Study Using National Health Insurance Database.

Authors:  Kyeongmin Kwak; Kyung Ehi Zoh; Domyung Paek
Journal:  Int J Environ Res Public Health       Date:  2021-01-20       Impact factor: 3.390

4.  Methodological issues in descriptive environmental epidemiology. The example of study Sentieri.

Authors:  Catalina Ciocan; Nicolò Franco; Enrico Pira; Ihab Mansour; Alessandro Godono; Paolo Boffetta
Journal:  Med Lav       Date:  2021-02-23       Impact factor: 1.275

5.  Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders.

Authors:  Eun-Kee Park; Anthony R Johnson; Donald Wilson; Paul S Thomas; Deborah H Yates
Journal:  Saf Health Work       Date:  2020-08-03

Review 6.  Domestic asbestos exposure: a review of epidemiologic and exposure data.

Authors:  Emily Goswami; Valerie Craven; David L Dahlstrom; Dominik Alexander; Fionna Mowat
Journal:  Int J Environ Res Public Health       Date:  2013-10-31       Impact factor: 3.390

7.  Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory.

Authors:  Luigi Vimercati; Domenica Cavone; Maria Celeste Delfino; Antonio Caputi; Luigi De Maria; Stefania Sponselli; Vincenzo Corrado; Giovanni Maria Ferri; Gabriella Serio
Journal:  Int J Environ Res Public Health       Date:  2020-04-12       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.